Key insights
- Major pharmaceutical companies are increasingly partnering with AI firms for drug discovery and development. Deals involving Sanofi, Bristol Myers Squibb, Gilead, Eli Lilly, Pfizer, and Takeda highlight a trend of leveraging AI to accelerate research, improve clinical trial selection, and reduce R&D costs. This suggests a significant growth area for AI applications within the healthcare sector, potentially boosting innovation and efficiency in drug development.
Sanofi just signed a new multi-year AI drug discovery deal with Owkin. The goal: Build AI-powered “biopharma agents” that can support drug discovery and development from early research through clinical trials. This is not an isolated deal. In 2026 alone: Sanofi partnered deeper with Owkin for AI drug discovery. Bristol Myers Squibb signed with Anthropic to roll out Claude across research, clinical development, manufacturing, commercial, and corporate teams. Gilead expanded its deal with Tempus AI for enterprise-wide access to AI tools and real-world oncology data. Eli Lilly partnered with Chai Discovery, Noetik, and Insilico Medicine. Pfizer signed with Boltz for custom AI models in antibody and small-molecule design. Takeda partnered with Iambic Therapeutics in a deal worth more than 1.7 Billion Dollars. Drug development is slow, expensive, and failure-heavy. AI is being positioned as the operating layer that can help pharma companies find better targets, design better molecules, improve trial selection, and reduce wasted R&D spending.